GlassScriptPhysician profile
Ahmad A Alratroot
NPI 1144673260
$1,636.22
in general payments reported to CMS, 2019-2025
26 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.13 · 2020: $23.67 · 2023: $203 · 2024: $706 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.37 |
| Education | $169.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $341.85 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Baxter Healthcare | $192.08 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $170.56 | 2023-2025 | Dupixent |
| United Therapeutics Corporation | $106.45 | 2024-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $95.44 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $59.87 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $56.83 | 2023-2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $56.33 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.72 | 2023-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $46.01 | 2024 | Yupelri |
| Insmed, INC. | $41.51 | 2023-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $40.68 | 2024 | Zerbaxa, Recarbrio |
| Genzyme Corporation | $40.38 | 2024 | |
| Edwards Lifesciences Corporation | $38.71 | 2019-2024 | Hemosphere |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $28.21 | 2025 | Yupelri |
| Hologic Sales and Service, LLC | $23.67 | 2020 | |
| Inogen, INC. | $22.60 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.11 | 2024 | |
| Electromed, INC. | $20.63 | 2025 | Smartvest |
| Grifols USA, LLC | $20.06 | 2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2024 | |
| Harmony Biosciences LLC | $19.17 | 2023 | Wakix |
| Philips North America LLC | $14.94 | 2025 | Vest Therapy Und |
| Novo Nordisk INC | $13.86 | 2019 | |
| La Jolla Pharmaceutical Company | $13.11 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Alratroot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.